Elutia (Nasdaq:ELUT) announced today that it entered into a securities purchase agreement worth total proceeds of $26.2 million. The drug-eluting biomatrix company expects the private placement financing to result in initial gross proceeds of approximately $10.5 million. The full exercise of warrants would add $15.8 million to reach a total of $26.2 million. Silver Spring, […]
Stem Cells
CellTrans wins FDA approval for first cell therapy that treats type 1 diabetes
The FDA announced that it approved the Lantidra allogeneic pancreatic islet cellular therapy developed by CellTrans to treat diabetes. It marks the first approval of a donor pancreatic cellular therapy — made from deceased donor pancreatic cells — to treat type 1 diabetes. The approval covers adults with type 1 diabetes who prove unable to […]
Lilly to acquire Sigilon, cell therapy for treating diabetes
Eli Lilly (NYSE:LLY) announced today that it entered a definitive agreement to acquire biopharmaceutical company Sigilon. Cambridge, Massachusetts-based Sigilon seeks to develop functional cures for patients with a range of acute and chronic diseases. The two companies have collaborated since 2018 to develop encapsulated cell therapies, including SIG-002. These therapies aim to treat type 1 […]
Sernova, AstraZeneca collaborate to deliver therapeutic cells with Sernova Cell Pouch
Sernova announced today that it entered into a preclinical research collaboration on drug delivery with AstraZeneca. The collaboration aims to evaluate the use of Sernova’s Cell Pouch System in combination with AstraZeneca’s novel therapeutic cells. London, Ontario-based Sernova designed its proprietary Cell Pouch System as an implantable and scalable medical device. It forms a natural […]
Vertex to acquire stem cell-derived diabetes treatment maker ViaCyte for $320M
Vertex Pharmaceuticals (Nasdaq:VRTX) announced today that it agreed to acquire ViaCyte for $320 million. San Diego-based ViaCyte develops an advanced portfolio of novel stem cell-derived replacement therapies designed to provide a functional cure for patients with type 1 diabetes. Boston-based Vertex develops its own similar therapeutic for diabetes, having designed its VX-880 as a stem […]
FDA grants breakthrough nod to Zetagen’s metastatic bone cancer treatment
Zetagen Therapeutics announced today that it received FDA breakthrough device designation for its ZetaMet cancer treatment technology. Syracuse, New York-based Zetagen designed its ZetaMet (previously known as ZetaFuse) as a synthetic, small-molecule, inductive biologic technology for targeting and resolving metastatic bone lesions while inhibiting future tumor growth and regenerating bone. According to a news release, […]
Magenta Therapeutics rises on Street-beating Q4
Magenta Therapeutics (NSDQ:MGTA) shares ticked up today on fourth-quarter earnings that topped the consensus forecast. The Cambridge, Mass.-based stem cell transplantation technology developer posted losses of -$18.2 million, or -38¢ per share for the three months ended Dec. 31, 2020, marking a 21.8% bottom-line gain. Magenta’s earnings per share of -38¢ came in 3¢ ahead […]
Frequency Therapeutics registers $100m IPO
Frequency Therapeutics has registered an initial public offering of common stock worth $100 million. Woburn, Mass.-based Frequency Therapeutics did not disclose the number of shares it seeks to sell or the price range of the offered units. The company applied to the Securities and Exchange Commission have its common stock listed on The Nasdaq Global […]
AxoSim touts results of nerve-on-a-chip study
A new study of AxoSim’s Nerve-on-a-Chip technology shows that the platform accurately provides key physiological readouts that could help speed the development of drugs to treat neurological disorders. The study also shows that Nerve-on-a-Chip technology is the first all-human in vitro model that can measure critical factors that were formerly only available using live animal models. […]
Anika collabs to develop injectable stem cell therapy for osteoarthritis
Anika Therapeutics (NSDQ:ANIK) has inked an agreement with the Institute of Integrative Biology at the University of Liverpool to develop an injectable mesenchymal stem cell therapy to treat osteoarthritis. As a result of the three-year research collaboration, the group hopes to have a lead candidate that it can take into clinical trials. “We are very excited […]
